Table Of Content

ELSsEaV I4E R Clinica Chimica Acta 279 (1999) 183-185 Author index Volume 279 (1999) Alhava, E., see Parviainen, M.T. 279, 145 Endoh, T., Yagihashi, A., Tanemura,_ K., Argov, Z., see Lev, E.l. 279, 107 Nishinosono, S., Matsukawa, M., Miyao, N., Arnala, L., see Parviainen, M.T. 279, 145 Tsukamoto, T., Watanabe, N., False-negative Ashkenazy, I., see Lev, E.l. 279, 107 rapid plasma reagin circle card test 279, 179 Baba, S., see Kinoshita, M. 279, 15 Faraggi, D., see Lev, E.I. 279, 107 Bachmair, F., Huber, Ch., Daxenbichler, G., Ferré-Masferrer, M., Fuentes-Arderiu, X., Puchal- Quantitation of gene expression by means of Ané, R., Indirect reference limits estimated from HPLC analysis of RT-PCR products 279, 25 patients’ results by three mathematical Bago, K., see Kinoshita, M. 279, 15 procedures 279, 97 Bogard, C., see Tchernitchko, D. 279, 133 Fruchart, J.-C., see Brites, F.D. 279, 1 Bourrouillou, G., see Vergnes, H. 279, 167 Fuentes-Arderiu, X., see Ferré-Masferrer, M. 279, Brites, F.D., Cavallero, E., de Geitere, C., 97 Nicolaiew, N., Jacotot, B., Rosseneu, M., Fruch- art, J.-C., Wikinski, R.L., Castro, G.R., Abnormal Gouya, L., see Tchernitchko, D. 279, 133 capacity to induce cholesterol efflux and a new Grozdea, J., see Vergnes, H. 279, 167 LpA-I pre-B particle in type 2. diabetic Gulian, J.-M., see Torri, G.M. 279, 77 patients 279, | Briihlmann, P., see Krahenbiihl, S. 279, 35 Hadama, T., see Kinoshita, M. 279, 15 Hiyoshi, S., see Tsuboi, I. 279, 175 Calapoglu, M., see Efe, H. 279, 155 Hoppeler, H., see Krahenbihl, S. 279, 35 Calvas, P., see Vergnes, H. 279, 167 Hoshino, H., see Takahashi, M. 279, 69 Castro, G.R., see Brites, F.D. 279, | Huber, Ch., see Bachmair, F. 279, 25 Cavallero, E., see Brites, F.D. 279, | Cozzone, P.J., see Torri, G.M. 279, 77 Ida, H., see Tsuboi, I. 279, 175 Imafuku, Y., see Ozawa, Y. 279, 125 Daxenbichler, G., see Bachmair, F. 279, 25 Inoue, M., see Meshitsuka, S. 279, 47 de Geitere, C., see Brites, F.D. 279, | Ishihara, Y., see Tatara, T. 279, 117 Deger, O., see Efe, H. 279, 155 Itoh, K., see Utsumi, K. 279, 55 Denier, C., see Vergnes, H. 279, 167 Iwao, Y., see Tatara, T. 279, 117 Deybach, J.C., see Tchernitchko, D. 279, 133 Jaiaskelainen, K., see Parviainen, M.T. 279, 145 Efe, H., Deger, O., Kirci, D., Karahan, $.C., Orem, Jacotot, B., see Brites, F.D. 279, | A., Calapoglu, M., Decreased neutrophil antioxidative enzyme activities and increased lipid Karahan, S.C., see Efe, H. 279, 155 peroxidation in hyperlipoproteinemic human Kase, R., see Utsumi, K. 279, 55 subjects 279, 155 Katagiri, Y., see Utsumi, K. 279, 55 PII: S009-8981(98)00204-6 184 Author index vol. 279 (1999) Kinoshita, M., Nakamura, J., Kusaka, H., Hadama, markers in monitoring treatment of symptomatic T., Bago, K., Kitajima, M., Baba, S., Automated osteoporosis 279, 145 and simultaneous identification of microsatellite Puchal-Ané, R., see Ferré-Masferrer, M. 279, 97 instability by fluorescence-based polymerase Puy, H., see Tchernitchko, D. 279, 133 chain reaction (PCR) in four loci 279, 15 Kirci, D., see Efe, H. 279, 155 Reiner, A., see Lev, E.l. 279, 107 Kitajima, M., see Kinoshita, M. 279, 15 Robreau, A.M., see Tchernitchko, D. 279, 133 Koeda, T., see Meshitsuka, S. 279, 47 Rosipal, R., see Tchernitchko, D. 279, 133 Rosseneu, M., see Brites, F.D. 279, 1 Kotani, M., see Utsumi, K. 279, 55 Krahenbihl, S., Willer, B., Briihimann, P., Hop- Sakuraba, H., see Utsumi, K. 279, 55 peler, H., Stucki, G., Carnitine homeostasis in Sato, S., see Ozawa, Y. 279, 125 patients with rheumatoid arthritis 279, 35 Sawai, T., see Tsuboi, I. 279, 175 Kréger, H., see Parviainen, M.T. 279, 145 Seki, A., see Meshitsuka, S. 279, 47 Kusaka, H., see Kinoshita, M. 279, 15 Shemer, J., see Lev, E.l. 279, 107 Kushida, K., see Takahashi, M. 279, 69 Shigenobu, F., see Tsuboi, I. 279, 175 Shimizu, M., see Tsuboi, |. 279, 175 Lamoril, J., see Tchernitchko, D. 279, 133 Shimmoto, M., see Utsumi, K. 279, 55 Lev, E.I., Tur-Kaspa, I., Ashkenazy, L., Reiner, A., Shishido, S., see Ozawa, Y. 279, 125 Faraggi, D., Shemer, J., Argov, Z., Distribution Stucki, G., see Krahenbiihl, S. 279, 35 of serum creatine kinase activity in young heal- thy persons 279, 107 Takahashi, M., Hoshino, H., Kushida, K., Measure- ments of urinary nonisomerized form of type I Matsukawa, M., see Endoh, T. 279, 179 collagen degradation products (a-CTx) in aging, Matsumoto, K., see Ozawa, Y. 279, 125 menopause, and osteoporosis with frac- Meshitsuka, S., Inoue, M., Seki, A., Koeda, T., tures 279, 69 Takeshita, K., Screening of urine by one-dimen- Takeda, J., see Tatara, T. 279, 117 sional and pulsed-field gradient two-dimensional Takeshita, K., see Meshitsuka, S. 279, 47 'H NMR spectroscopy: intoxication by propylene Tanemura, K., see Endoh, T. 279, 179 glycol in an infant patient 279, 47 Taniguchi, K., see Tsuboi, I. 279, 175 Miura, Y., see Ozawa, Y. 279, 125 Tanoue, K., see Utsumi, K. 279, 55 Miyao, N., see Endoh, T. 279, 179 Tatara, T., Iwao, Y., Takeda, J., Ishihara, Y., Mizuoka, K., see Tsuboi, 1. 279, 175 Ohkochi, S., Uedaira, H., Proton nuclear magnetic resonance spectroscopy of urine for rapid Nakamura, J., see Kinoshita, M. 279, 15 multicomponent analysis of intraoperative cel- Nakayama, I., see Tsuboi, I. 279, 175 lular metabolites 279, 117 Nicolaiew, N., see Brites, F.D. 279, 1 Tchernitchko, D., Lamoril, J., Puy, H., Robreau, Nishi, S., see Ozawa, Y. 279, 125 A.M., Bogard, C., Rosipal, R., Gouya, L., Nishinosono, S., see Endoh, T. 279, 179 Deybach, J.C., Nordmann, Y., Evaluation of Nonomiya, T., see Tsuboi, 1. 279, 175 mutation screening by heteroduplex analysis in Nordmann, Y., see Tchernitchko, D. 279, 133 acute intermittent porphyria: comparison with denaturing gradient gel electrophoresis 279, Oguchi, T., see Utsumi, K. 279, 55 133 O'Hara, K., see Tsuboi, 1. 279, 175 Torri, G.M., Torri, J., Gulian, J.-M., Vion-Dury, J., Ohkochi, S., see Tatara, T. 279, 117 Viout, P., J. Cozzone, P., Magnetic resonance Orem, A., see Efe, H. 279, 155 spectroscopy of serum and acute-phase proteins Ozawa, T., see Utsumi, K. 279, 55 revisited: a multiparametric statistical analysis of Ozawa, Y., Sato, S., Matsumoto, K., Nishi, S., metabolite variations in inflammatory, infectious Shishido, S., Imafuku, Y., Miura, Y., Yoshida, H., and miscellaneous diseases 279, 77 Determination of potassium flux activity of Torri, J., see Torri, G.M. 279, 77 viable human erythrocytes by measuring the Tsuboi, I., Ida, H., Yoshikawa, E., Hiyoshi, S., release-influx ratio 279, 125 Yamaji, E., Nakayama, I., O’Hara, K., Nonomiya, T., Shigenobu, F., Taniguchi, K., Parviainen, M.T., Jaaskelainen, K., Kroger, H., Shimizu, M., Sawai, T., Mizuoka, K., Uptake of Arnala, I., Alhava, E., Urinary bone resorption [“H]-fosfomycin into cells of enterohemorrhagic Author index vol. 279 (1999) Escherichia coli O57 and E. coli non- Vion-Dury, J., see Torri, G.M. 279, 77 O157 279, 175 Viout, P., see Torri, G.M. 279, 77 Tsukamoto, T., see Endoh, T. 279, 179 Tur-Kaspa, L., see Lev, El. 279, 107 Watanabe, N., see Endoh, T. 279, 179 Wikinski, R.L., see Brites, F.D. 279, 1 Uedaira, H., see Tatara, T. 279, 117 Willer, B., see Krahenbiihl, S. 279, 35 Utsumi, K., Itoh, K., Kase, R., Shimmoto, M., Yamamoto, N., Katagiri, Y., Tanoue, K., Kotani, Yagihashi, A., see Endoh, T. 279, 179 M., Ozawa, T., Oguchi, T., Sakuraba, H., Urin- Yamaji, E., see Tsuboi, 1. 279, 175 ary excretion of the vitronectin receptor (integrin Yamamoto, N., see Utsumi, K. 279, 55 a,B,) in patients with Fabry disease 279, 55 Yoshida, H., see Ozawa, Y. 279, 125 Yoshikawa, E., see Tsuboi, |. 279, 175 Vergnes, H., Grozdea, J., Denier, C., Bourrouillou, G., Calvas, P., Expression of a liver/bone—in- testinal hybrid of alkaline phosphatase in neutrophils of Down’s syndrome patients 279, 167 ELSEVIER Clinica Chimica Acta 279 (1999) 187-189 Subject index Volume 279 (1999) Acute phase proteins; MRS spectroscopy; Serum Bone marker; Bone resorption; Vertebral fracture; proteins; Principal component analysis; Inflam- Hip fracture 279, 69 mation 279, 77 Bone resorption; Bone marker; Vertebral fracture; Aging; Human erythrocytes; K" flux; Release-in- Hip fracture 279, 69 flux ratio; Na’ /K*-exchanging ATPase 279, 125 Carnitine; Rheumatoid arthritis; Muscle strength; Fatty acid metabolism; Carnitine palmitoyltran- AIP, acute intermittent porphyria; PBGD, por- sferase 279, 35 phobilinogen deaminase; DDGE, denaturing gradient gel electrophoresis; HA, heteroduplex analysis 279, 133 Carnitine palmitoyltransferase, Rheumatoid arthritis; Muscle strength; Fatty acid metabolism; Alcohol; Creatine kinase; Myoglobin; Physical Carnitine 279, 35 activity; BMI 279, 107 Cholesterol efflux; Type 2 diabetes; Postprandial Alkaline phosphatase; Hybrid isoenzyme; Neutro- lipemia; Apolipoprotein A-I; Pre-B-HDL 279, | phils; Down’s syndrome 279, 167 Creatine kinase; Myoglobin; Physical activity; Antioxidants; Hyperlipoproteinemia; Antioxidative BMI; Alcohol 279, 107 enzymes; Lipid peroxidation; Neutrophil 279, 155 DDGE, denaturing gradient gel electrophoresis: AIP, acute intermittent porphyria; PBGD, por- Antioxidative enzymes; Hyperlipoproteinemia; phobilinogen deaminase; HA, heteroduplex anal- Antioxidants, Lipid peroxidation; Neutrophil ysis 279, 133 279, 155 Deoxypyridoline crosslinks; Fracture; Hormone Apolipoprotein A-I; Type 2 diabetes; Postprandial therapy; N-telopeptide of Type I collagen; Os- lipemia; Cholesterol efflux; Pre-B-HDL 279, | teoporosis; Postmenopausal women 279, 145 Autosequencer; Microsatellite instability; Replica- tion error; Microsatellite repeats; Loss of hetero- Down’s syndrome; Alkaline phosphatase; Hybrid zygosity 279, 15 isoenzyme; Neutrophils 279, 167 BMI, Creatine kinase; Myoglobin; Physical activi- Enterohemorrhagic Escherichia coli, 0157; Up- ty; Alcohol 279, 107 take; Fosfomycin 279, 175 PII: $009-8981(98)00205-8 188 Subject index vol. 279 (1999) Fatty acid metabolism; Rheumatoid arthritis; K* flux; Human erythrocytes; Release-influx ratio; Muscle strength; Carnitine; Carnitine _ pal- Na’ /K~-exchanging ATPase; Aging 279, 125 mitoyltransferase 279, 35 Lipid peroxidation; Hyperlipoproteinemia; An- Fosfomycin; Enterohemorthagic Escherichia coli; tioxidative enzymes; Antioxidants; Neutrophil O157; Uptake 279, 175 279, 155 Fracture; Deoxypyridoline crosslinks; Hormone Loss of heterozygosity; Microsatellite instability; therapy; N-telopeptide of Type I collagen; Os- Replication error; Autosequencer; Microsatellite teoporosis; Postmenopausal women 279, 145 repeats 279, 15 Gene expression; Quantitation; Reverse transcrip- Metabolism; Nuclear magnetic resonance; Proton; tion—polymerase chain reaction; HPLC analysis Surgery; Urine 279, 117 279, 25 MFabry disease; Globotriaosylceramide; Vitronec- Globotriaosylceramide, MFabry disease; Vitronec- tin receptor; Vitronectin 279, 55 tin receptor; Vitronectin 279, 55 Microsatellite instability; Replication error; Au- ‘H NMR; Propylene glycol; PFG-DQF-COSY; tosequencer, Microsatellite repeats; Loss of Intoxication; Urine 279, 47 heterozygosity 279, 15 HA, heteroduplex analysis; AIP, acute intermittent Microsatellite repeats; Microsatellite instability; porphyria, PBGD, porphobilinogen deaminase: Replication error; Autosequencer, Loss of DDGE, denaturing gradient gel electrophoresis heterozygosity 279, 15 279, 133 MRS spectroscopy; Serum proteins; Acute phase Hip fracture; Bone marker; Bone resorption; proteins; Principal component analysis; Inflam- Vertebral fracture 279, 69 mation 279, 77 Hormone therapy: Deoxypyridoline crosslinks; Muscle strength; Rheumatoid arthritis; Fatty acid Fracture; N-telopeptide of Type I collagen; Os- metabolism; Carnitine; Carnitine palmitoyltran- teoporosis; Postmenopausal women 279, 145 sferase 279, 35 HPLC analysis; Quantitation; Gene expression; Myoglobin; Creatine kinase; Physical activity; Reverse transcription—polymerase chain reaction BMI; Alcohol 279, 107 279, 25 N-telopeptide of Type I collagen; Deoxy- Human erythrocytes; K° flux; Release-influx pyridoline crosslinks; Fracture; Hormone ratio; Na /K “-exchanging ATPase; Aging 279, therapy; Osteoporosis; Postmenopausal women 125 279, 145 Hybrid isoenzyme, Alkaline phosphatase; Neutro- Na*/K*-exchanging ATPase; Human erythro- phils; Down's syndrome 279, 167 cytes; K” flux; Release-influx ratio; Aging 279, 125 Hyperlipoproteinemia; Antioxidative enzymes; Antioxidants; Lipid peroxidation; Neutrophil Neutrophil; Hyperlipoproteinemia; Antioxidative 279, 155 enzymes; Antioxidants; Lipid peroxidation 279, 155 Inflammation; MRS spectroscopy; Serum proteins; Acute phase proteins; Principal component anal- Neutrophils; Alkaline phosphatase; Hybrid iso- ysis 279, 77 enzyme; Down's syndrome 279, 167 PFG-DQF- Intoxication, Propylene glycol; Nuclear magnetic resonance; Metabolism; Proton; COSY; 'H NMR; Urine 279, 47 Surgery; Urine 279, 117 Subject index vol. 279 (1999) 189 O157; Enterohemorrhagic Escherichia coli; Up- Release-influx ratio; Human erythrocytes; K’ take; Fosfomycin 279, 175 flux; Na’ /K -exchanging ATPase; Aging 279, 125 Osteoporosis; Deoxypyridoline crosslinks; Frac- ture; Hormone therapy; N-telopeptide of Type | Replication error; Microsatellite instability; Au- collagen; Postmenopausal women 279, 145 tosequencer, Microsatellite repeats; Loss of heterozygosity 279, 15 Patients’ results; Reference values; Statistical methods 279, 97 Reverse transcription—polymerase chain _re- action; Quantitation; Gene expression; HPLC PBGD, porphobilinogen deaminase, AIP. acute analysis 279, 25 intermittent porphyria; DDGE, denaturing gradient gel electrophoresis; HA, heteroduplex anal- Rheumatoid arthritis; Muscle strength; Fatty acid ysis 279, 133 metabolism; Carnitine; Carnitine palmitoyltransferase 279, 35 PFG-DQF-COSY; Propylene glycol; 'H NMR; Intoxication; Urine 279, 47 Serum proteins; MRS spectroscopy; Acute phase proteins; Principal component analysis; Inflam- Physical activity; Creatine kinase; Myoglobin; mation 279, 77 BMI; Alcohol 279, 107 Statistical methods; Reference values: Patients’ Postmenopausal women; Deoxypyridoline cros- results 279, 97 slinks; Fracture; Hormone therapy; N-telopeptide of Type I collagen; Osteoporosis 279, 145 Surgery; Nuclear magnetic resonance; Metabolism; Proton; Urine 279, 117 Postprandial lipemia; Type 2 diabetes; Choles- terol efflux; Apolipoprotein A-I; Pre-B-HDL Syphilis; Rapid plasma reagin (RPR) circle card 279. | test 279, 179 Pre-B-HDL; Type 2. diabetes; Postprandial Type 2 diabetes; Postprandial lipemia; Cholesterol lipemia; Cholesterol efflux; Apolipoprotein A-I efflux; Apolipoprotein A-I; Pre-B-HDL 279, | 279. | Uptake; Enterohemorrhagic Escherichia coli: Principal component analysis; MRS _spectros- O157; Fosfomycin 279, 175 copy: Serum proteins; Acute phase proteins; Inflammation 279, 77 Urine; Nuclear magnetic resonance; Metabolism; Proton; Surgery 279, 117 Propylene glycol; PPG-DQF-—COSY:; ‘H NMR: Intoxication; Urine 279, 47 Urine; Propylene glycol; PFG-DQF-COSY; 'H NMR; Intoxication 279, 47 Proton; Nuclear magnetic resonance; Metabolism; Surgery; Urine 279, 117 Vertebral fracture; Bone marker; Bone resorption; Hip fracture 279, 69 Quantitation; Gene expression; Reverse transcription—polymerase chain reaction; HPLC analysis Vitronectin receptor, MFabry disease; Globotria- 279, 25 osylceramide; Vitronectin 279, 55 Rapid plasma reagin (RPR) circle card test; Vitronectin; MFabry disease; Globotria- Syphilis 279, 179 osylceramide; Vitronectin receptor 279, 55 Reference values: Statistical methods: Patients’ results 279, 97